BRAF mutation - Revision history

Michael: /* General */

2019-01-23T18:20:38Z

General

← Older revision		Revision as of 18:20, 23 January 2019
Line 2:		Line 2:

	==General==		==General==
	*Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>		*Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>

	===Prevalence===		===Prevalence===

Michael at 18:20, 23 January 2019

2019-01-23T18:20:22Z

← Older revision		Revision as of 18:20, 23 January 2019
Line 1:		Line 1:
	'''BRAF mutation''' is a common genetic change in [[cancer]]. The most common BRAF mutation is the so-called [[BRAF V600E mutation]].		'''BRAF mutation''' is a common genetic change in [[cancer]]. The most common BRAF mutation is the so-called ''[[BRAF V600E mutation]]''.

	==General==		==General==

Michael at 18:17, 23 January 2019

2019-01-23T18:17:58Z

← Older revision		Revision as of 18:17, 23 January 2019
Line 1:		Line 1:
	'''BRAF mutation''' is a common genetic change in [[cancer]].		'''BRAF mutation''' is a common genetic change in [[cancer]]. The most common BRAF mutation is the so-called [[BRAF V600E mutation]].

	==General==		==General==
Line 11:		Line 11:
	*BRAF mutations in ~45-50% of papillary thyroid carcinoma.		*BRAF mutations in ~45-50% of papillary thyroid carcinoma.
	*BRAF mutations in ~3% of [[lung adenocarcinoma]]s.		*BRAF mutations in ~3% of [[lung adenocarcinoma]]s.

			==See also==
			*[[BRAF V600E mutation]].
			*[[KRAS mutation]].

	==References==		==References==

Michael: /* General */

2019-01-23T18:16:38Z

General

← Older revision		Revision as of 18:16, 23 January 2019
Line 2:		Line 2:

	==General==		==General==
	*BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>		*Clinical implication: BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>

	Prevalence by tumour type:<ref name=pmid29148538/>		===Prevalence===
			BRAF mutations by tumour type:<ref name=pmid29148538/>
	*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.		*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
	*BRAF mutations in ~ 10% of colorectal tumours.		*BRAF mutations in ~ 10% of colorectal tumours.

Michael at 18:15, 23 January 2019

2019-01-23T18:15:50Z

← Older revision		Revision as of 18:15, 23 January 2019
Line 3:		Line 3:
	==General==		==General==
	*BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>		*BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal \| last1 = Cheng \| first1 = L. \| last2 = Lopez-Beltran \| first2 = A. \| last3 = Massari \| first3 = F. \| last4 = MacLennan \| first4 = GT. \| last5 = Montironi \| first5 = R. \| title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. \| journal = Mod Pathol \| volume = 31 \| issue = 1 \| pages = 24-38 \| month = 01 \| year = 2018 \| doi = 10.1038/modpathol.2017.104 \| PMID = 29148538 }}</ref>
	**BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
	**BRAF mutations in ~ 10% of colorectal tumours.		Prevalence by tumour type:<ref name=pmid29148538/>
	***Poor prognosticator, poor response to chemotherapy, typically right sided tumours.		*BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
	**BRAF mutations in ~45-50% of papillary thyroid carcinoma.		*BRAF mutations in ~ 10% of colorectal tumours.
	**BRAF mutations in ~3% of [[lung adenocarcinoma]]s.		**Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
			*BRAF mutations in ~45-50% of papillary thyroid carcinoma.
			*BRAF mutations in ~3% of [[lung adenocarcinoma]]s.

	==References==		==References==

Michael: create

2019-01-23T18:15:19Z

create

New page

'''BRAF mutation''' is a common genetic change in [[cancer]].

==General==
*BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref>
**BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
**BRAF mutations in ~ 10% of colorectal tumours.
***Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
**BRAF mutations in ~45-50% of papillary thyroid carcinoma.
**BRAF mutations in ~3% of [[lung adenocarcinoma]]s.

==References==
{{Reflist|1}}

[[Category:Molecular pathology]]